U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details


; ; .

Author Information and Affiliations

Last Update: June 5, 2023.

Continuing Education Activity

Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet. It is a semi-synthetic derivative of lovastatin, the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke. However, there are several more effective statins with more favorable adverse effect profiles. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, and monitoring, of simvastatin, so providers can direct patient therapy in treating hyperlipidemia as part of the interprofessional team.


  • Identify the mechanism of action of simvastatin.
  • Review the indications for using simvastatin in lipid control.
  • Explain the adverse event profile of simvastatin and how it compares with other statin medications.
  • Summarize interprofessional team strategies for improving care coordination and communication to examine simvastatin use and improve patient outcomes.
Access free multiple choice questions on this topic.


Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet, exercise, weight loss, and possibly other medications as part of an overall lipid-lowering and cardiovascular health regimen. It is a semi-synthetic derivative of lovastatin, the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke.

FDA-Approved Indications

  • Homozygous/heterozygous familial hypercholesterolemia
  • Heterozygous NonFamilial hypercholesterolemia
  • Hypertriglyceridemia
  • Dysbetalipoproteinemia 
  • Reduction of adverse cardiovascular events 

Simvastatin is also used off-label for prophylactic and therapeutic indications.

Non-FDA-Approved Indications

  • Prophylaxis of adverse cardiovascular outcomes post-acute-coronary-syndrome hospitalization 
  • Prophylaxis of atrial fibrillation among patients with stable coronary artery disease

Simvastatin is used as monotherapy and is available in combination products to treat dyslipidemia. Combination products include:

  • Simvastatin/ezetimibe[1]
  • Simvastatin/niacin extended-release (ER)

Mechanism of Action

Clinicians prescribe statin therapy to lower cholesterol concentrations; simvastatin targets cholesterol production. The biosynthesis of this molecule consists of a multi-step pathway. The rate-limiting step in this pathway involves the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase enzyme. Using acetyl-CoA as a substrate, mevalonic acid is formed, and subsequent reactions lead to the formation of cholesterol. Simvastatin acts on the rate-limiting step and serves as an HMG-CoA reductase inhibitor, consequently leading to decreased cholesterol concentrations.

Statins also possess additional properties in addition to their ability to lower cholesterol concentrations. These include inhibition of platelet aggregation, reduction in inflammation at the site of atherosclerotic plaque, and improved endothelial function. These properties are commonly taken advantage of when prescribing statin therapy for individuals with normal cholesterol levels. Studies have shown that early statin therapy initiation has reduced the incidence of cardiovascular events, leading to reduced mortality.[2]

Simvastatin is hepatically metabolized via the CYP450 enzyme system, primarily through CYP3A4 as well as CYP2C6; this figures prominently in some of its potential adverse effects and drug-drug interactions, of which more later. It is a prodrug. It is excreted in the feces and urine and has a half-life of between two and five hours.


Simvastatin is approved for oral administration and is available in 5-mg, 10-mg, 20-mg, 40-mg, and 80-mg tablets. A suspension dosage form is also available for those with difficulty swallowing.

Recommended Dosages*

Homozygous Familial Hypercholesterolemia

  • 40 mg once every evening

Heterozygous Familial Hypercholesterolemia

  • Initial 10 to 20 mg once every evening; max dose 40 mg once every evening
  • Pediatric patients age 10 to 17: Initial 10 mg once every evening; max dose 40 mg once every evening


  • Initial 10 to 20 mg once every evening; max dose 40 mg once every evening

Reduction in Cardiovascular Events

  • Initial 10 to 20 mg once every evening; max dose 40 mg once every evening
  • In patients with coronary heart disease (CHD), the initial dose is 40 mg once every evening

A dose restriction exists for simvastatin 80 mg due to a higher risk of myopathy and possible rhabdomyolysis, especially within the first 12 months of use. Therefore, the 80-mg strength is restricted for only those patients who have been on the 80-mg regimen for 12 or more months with no reported myopathy. Simvastatin 80 mg is not recommended for patients with LDL targets that are not at goal, even with simvastatin 40 mg. Recommendations are to use a high-intensity statin instead. For stable patients on the simvastatin 80-mg dose, a change of therapy is necessary if initiating an interacting medication.

*Doses are adjusted to target goal LDL levels.

Dose Adjustments

Dose adjustments are necessary with simvastatin when taken concomitantly with certain pharmacotherapy. Adjustments in simvastatin strength reduce potential statin-associated toxicities, including fatigue and myopathy.

Potent CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors, cyclosporine)

  • Simvastatin is contraindicated:
    • Verapamil, diltiazem, dronedarone
      • Max dose is simvastatin 10 mg
    • Amiodarone, amlodipine, ranolazine
      • Max dose is simvastatin 20 mg

Adverse Effects

Common adverse effects include headaches, myalgia, abdominal pain, gastritis, constipation, upper respiratory infections, elevated AST or ALT, and impaired serum glucose control.[3]

Rarer, yet more severe, causations include cardiovascular effects such as atrial fibrillation, hepatic abnormalities, including cholestatic hepatitis, greater than a 3-fold elevation in transaminases, jaundice, and potential liver failure. Adverse musculoskeletal effects include greater than a three-fold increase in creatine phosphokinase (CPK) levels, rhabdomyolysis, and compartment syndrome in the lower legs.[4][5][6]

Additional serious reactions include interstitial lung disease, diabetes mellitus, erythema multiforme, leukopenia, hemolytic anemia, thrombocytopenia, and Stevens-Johnson syndrome, although these adverse events are rare. 

Drug concentrations, and consequently, incidence and severity of adverse effects, can become significantly increased when coadministered with CYP3A4 inhibitors. Concomitant medications administered with simvastatin should have an assessment performed for potential drug interactions to minimize the risk of adverse effects. Patients are commonly advised to stop eating grapefruits or drinking grapefruit juice while on statin therapy. However, more recent research has shown this risk can be minimized by spacing the consumption of grapefruit and statin dosing.[7]


Patients with contraindications to simvastatin pharmacotherapy include those with active liver disease, including those who have elevated hepatic enzymes, pregnancy, and women who may become pregnant or who are breastfeeding. Concomitant use with certain medications (see above) is also a contraindication with simvastatin, and drug profiles should undergo a careful review prior to initiation.

Pregnancy is a known secondary cause of dyslipidemia, leading to a potential increase in triglyceride and LDL-C concentrations. Statin therapy is contraindicated during pregnancy resulting in limited options for dyslipidemia treatment during pregnancy. Alternative treatment options are necessary to treat elevated concentrations during pregnancy to minimize associated complications such as hypertriglyceridemia related to acute pancreatitis. Pregnancy has been delayed or avoided in reported cases to avoid the possible complications from untreated dyslipidemia.[8] Females of child-bearing potential are advised to use appropriate contraception during treatment with simvastatin. Recommendations are also to avoid breastfeeding if possible; if unavoidable, clinicians need to weigh potential benefits vs. risk profile, although there is no current data on infant harm or adverse effects on breast milk production.[9]

Although rare, a serious complication of statin therapy is liver toxicity with elevated levels of transaminases. Due to a potential increase in liver enzymes, patients with active liver disease and pre-existing elevated transaminases are excluded from simvastatin therapy. Simvastatin can transiently increase transaminase concentrations within the first few months of treatment. These subsequently return to baseline. The clinician should monitor liver function and enzymes while their patients are on simvastatin pharmacotherapy.[10]

Contraindicated drugs for concomitant use with simvastatin include atazanavir, chloramphenicol, erythromycin, gemfibrozil, ritonavir, and azole antifungals. This is not an exhaustive list, and complete medication reconciliation is recommended, as with any drug regimen.[11]


Continuous laboratory monitoring is not necessary for patients on simvastatin therapy. To gauge therapeutic effectiveness, a lipid profile is evaluated four weeks after initiation and periodically after that leading to potential dose adjustments. Liver function tests are also performed at baseline and subsequently, as clinically necessitated, to evaluate liver toxicities. Common symptoms include abdominal pain, yellowing of the skin, loss of appetite, and fatigue. Creatine kinase levels are also assessed at baseline and periodically after that, especially in high-risk patients such as those with renal insufficiency. Patients with complex medication profiles (polypharmacy) require close monitoring for musculoskeletal and hepatic complaints due to potential simvastatin toxicities and possible drug-drug interactions.[12]


Severe cases of musculoskeletal symptoms warrant discontinuation of simvastatin. In milder cases, the currently accepted practice is temporary discontinuation followed by a re-challenge at a lower dose. If re-challenging simvastatin at a lower dose leads to similar adverse effects, discontinuation followed by an alternative statin is the recommended next step.[13] Discontinuation is also warranted if severe hepatotoxicity or hyperbilirubinemia or if jaundice occurs.

Enhancing Healthcare Team Outcomes

Simvastatin has been used for many years to treat dyslipidemia and high-risk patients such as people with diabetes. Common clinical pearls can help limit potential adverse effects and enhance patient outcomes.

  • Due to an increased risk of myopathy, the 80-mg dose is restricted to patients who have been stable on 80 mg for at least 12 months. If additional LDL-lowering is required, switch to a high-intensity statin.
  • Use a lower starting dose and monitor for patients who are of Chinese descent.[14]
  • Use further caution in patients who are chronic alcohol consumers and/or have a history of liver disease.
  • Avoid the consumption of grapefruit juice, or space the consumption of grapefruit and grapefruit juice from statin dosing.[7]

Simvastatin therapy can address dyslipidemia in those patients with such a profile. However, newer statin agents with fewer interactions and adverse effects have replaced simvastatin as the first-line agent for statin therapy. Currently, it is more common to initiate treatment on these newer agents, leaving simvastatin for those who have had successful results using the drug with no adverse events. For those patients who receive dyslipidemia therapy with simvastatin, the interprofessional healthcare team, consisting of clinicians (MDs, DOs, NPS, and PAs), specialists, nurses, and pharmacists, should work together to monitor for therapeutic results and adverse effects and the pharmacist can suggest equivalent dosing with other statins less prone to adverse events.

When the clinician prescribes simvastatin, the nursing staff should review dosing and administration with the patient and answer patient questions about their medication therapy. It is incumbent on the pharmacist to perform medication reconciliation and verify that there are no potential drug-drug interactions that need to be addressed and that the dosing of the drug is appropriate. Any concerns should be reported to the prescriber or nursing staff, so appropriate measures can be taken to alter the patient's therapy.[15] All interprofessional team members should be vigilant for adverse events and immediately report them to the rest of the team. This interprofessional approach can drive better patient outcomes with fewer side effects. [Level 5]

Review Questions


Gryn SE, Hegele RA. Ezetimibe plus simvastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2015 Jun;16(8):1255-62. [PubMed: 25920750]
De Denus S, Spinler SA. Early statin therapy for acute coronary syndromes. Ann Pharmacother. 2002 Nov;36(11):1749-58. [PubMed: 12398573]
Trias F, Pintó X, Corbella E, Suárez-Tembra M, Ruíz-García A, Díaz-Díaz JL, Sánchez-Ruíz-Granado E, Sarasa I, Martínez-Porqueras R, Rodríguez-Sánchez MA, Corbella X., PRELIPID Study Group. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc). 2022 Jun 10;158(11):531-539. [PubMed: 34517987]
Chochola M, Lubanda JC, Skalicka L, Varejka P, Horejs J, Prskavec T, Balík M, Semrád M, Linhart A. [Bilateral leg compartment syndrome due to severe myonecrosis caused by inappropriate use of simvastatin]. J Mal Vasc. 2008 Dec;33(4-5):229-33. [PubMed: 18819764]
Parkin L, Paul C, Herbison GP. Simvastatin dose and risk of rhabdomyolysis: nested case-control study based on national health and drug dispensing data. Int J Cardiol. 2014 Jun 01;174(1):83-9. [PubMed: 24726164]
Somagutta MKR, Shama N, Pormento MKL, Jagani RP, Ngardig NN, Ghazarian K, Mahmutaj G, El-Faramawy K, Mahadevaiah A, Jain MS. Statin-induced necrotizing autoimmune myopathy: a systematic review. Reumatologia. 2022;60(1):63-69. [PMC free article: PMC9132114] [PubMed: 35645423]
Lee JW, Morris JK, Wald NJ. Grapefruit Juice and Statins. Am J Med. 2016 Jan;129(1):26-9. [PubMed: 26299317]
Russi G. Severe dyslipidemia in pregnancy: The role of therapeutic apheresis. Transfus Apher Sci. 2015 Dec;53(3):283-7. [PubMed: 26626968]
Comparison table: Some lipid-lowering drugs. Med Lett Drugs Ther. 2019 Feb 11;61(1565):e24-e30. [PubMed: 30845107]
Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010 Apr;85(4):349-56. [PMC free article: PMC2848423] [PubMed: 20360293]
Laufs U, Weingärtner O, Kassner U, Schatz U. [State of the Art: Statin Therapy]. Dtsch Med Wochenschr. 2022 Jan;147(1-02):62-68. [PMC free article: PMC8789540] [PubMed: 34872149]
Page SR, Yee KC. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. Intern Med J. 2014 Jul;44(7):690-3. [PubMed: 25041770]
Taylor BA, Panza G, Thompson PD. Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms. Int J Cardiol. 2016 Apr 15;209:12-3. [PMC free article: PMC6106859] [PubMed: 26874453]
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 Feb 01;99(3):410-4. [PMC free article: PMC2651637] [PubMed: 17261409]
Hamadouk RM, Albashair ED, Mohammed FM, Yousef BA. The Practice of the Community Pharmacists in Managing Potential Drug-Drug Interactions: A Simulated Patient Visits. Integr Pharm Res Pract. 2022;11:71-84. [PMC free article: PMC8934170] [PubMed: 35313632]

Disclosure: Om Talreja declares no relevant financial relationships with ineligible companies.

Disclosure: Connor Kerndt declares no relevant financial relationships with ineligible companies.

Disclosure: Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK532919PMID: 30422514


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...